The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Clofarabine in Chronic Lymphocytic Leukemia
Official Title: Phase I Study of CL-F-ARA-A in Solid and Hematologic Malignancies
Study ID: NCT00028418
Brief Summary: This is a dose-escalation study to determine the maximum tolerated dose and toxic effects of clofarabine in patients with chronic lymphocytic leukemia and other acute leukemias. Clofarabine is a synthesized hybrid nucleoside analog, which is believed to possess the better qualities of fludarabine and chlorodeoxyadenosine, the 2 most active agents against lymphoproliferative disorders. Thus, it is hoped that this drug will be more active and less toxic than similar drugs.
Detailed Description: The first group of patients will be treated at the starting dose level of 2 mg/m2 over 1 hour daily for 5 days. Dosage escalation will be permitted in individual patients if no toxicity occurred during the preceding course. Subsequent dose escalations will be by 50% until Grade 2 toxicity, then by 35% until the maximum tolerated dose. Completion date provided represents the completion date of the grant per OOPD records
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Name: Hagop M. Kantarjian, M.D.
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR